NCT01250470: Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma |
|
|
| Completed | 1 | 9 | US | Laboratory Biomarker Analysis, Montanide ISA-51/Survivin Peptide Vaccine, Sargramostim, 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, Leukine, Prokine, rhu GM-CFS, Sagramostim, Sargramostatin | Roswell Park Cancer Institute, National Cancer Institute (NCI) | Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma, Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma, Mixed Glioma, Recurrent Brain Neoplasm | 05/14 | 05/14 | | |
